SAN DIEGO, Aug. 4, 2015 /PRNewswire/ -- Organovo Holdings,
Inc. (NYSE MKT: ONVO; "Organovo"), a three-dimensional biology
company focused on delivering scientific and medical breakthroughs
using 3D bioprinting technology, today announced that the Company
has hired Paul Gallant as its
General Manager of the in vitro tissue service and product
business. Mr. Gallant has more than 20 years of management and
R&D experience in the drug discovery industry, most recently
serving as chief operating officer for DiscoveRx, a global
scientific product and services company. At Organovo, Mr.
Gallant will be responsible for driving the success of the
toxicology contract research services business, in close
partnership with the sales and marketing team under Michael Renard and the Research and Development
team under Sharon Presnell.
"Paul has an impressive track record in creating business units
and growing commercial operations to serve customers focused on
research and development of innovative therapeutics," said
Keith Murphy, chairman and chief
executive officer of Organovo. "Paul's experience in advancing
new technology platforms in collaboration with pharmaceutical
companies, contract research organizations and academic
institutions will be invaluable as he develops and executes
strategies for growing our business."
"Organovo offers a unique technology that has the potential to
transform toxicology testing and drug development for the
pharmaceutical industry, as well as develop long-range applications
in organ replacement," said Mr. Gallant. "I look forward to
building Organovo's customer base and developing and implementing
strategies to advance Organovo's products to realize the promise of
3D bioprinting."
As chief operating officer at DiscoveRx, Mr. Gallant was
responsible for the P&L results of the company's largest
business unit, managing drug discovery services. Mr. Gallant
formerly served as senior director at Ambit Pharmaceuticals,
acquired by DiscoveRx in 2010, where he led the development and
commercialization for the KINOMEscan platform. The world's largest
commercial kinase screening panel, KINOMEscan became a key element
of DiscoveRx's offering post-acquisition.
Mr. Gallant has also led R&D and service teams at Amgen,
Inc., Millennium Pharmaceuticals, Inc., Cubist Pharmaceuticals
Inc., and Massachusetts General Hospital. He earned a B.A. in
biology from Colby University.
Organovo's 3D bioprinting enables the reproducible, automated
creation of living human tissues that mimic the form and function
of native tissues in the body. The company recently announced
collaborations with L'Oreal to produce skin tissue for research and
toxicity testing, with Merck to print liver and kidney tissues for
studies of drug toxicity, and with Yale School
of Medicine to develop 3D organ tissues for surgical
transplantation research. Fast Company named Organovo one of The
World's Top 10 Most Innovative Companies of 2015 in Health
Care.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for use in medical research and therapeutic applications.
The Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo's 3D human tissues have the potential to
accelerate the drug discovery process, enabling treatments to be
developed faster and at lower cost. The company recently launched
its initial product of the planned exVive3DTM portfolio
offering, a 3D Human Liver Tissue for use in Toxicology and other
preclinical drug testing. Additional products are in development,
with anticipated release for an exVive3D™ Human Kidney Tissue in
the latter half of calendar year 2016. The Company also actively
conducts early research on specific tissues for therapeutic use in
direct surgical applications. In addition to numerous scientific
publications, the Company's technology has been featured in The
Wall Street Journal, Time Magazine, The Economist, and numerous
other media outlets. Organovo is changing the shape of medical
research and practice. Learn more at www.organovo.com.
Sign up for email updates and connect with us
on Twitter (@Organovo).
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-appoints-paul-gallant-as-general-manager-300122849.html
SOURCE Organovo Holdings, Inc.